spacer
home > ict > autumn 2009 > different countries, different approaches
PUBLICATIONS
International Clinical Trials

Different Countries, Different Approaches

 

Since the establishment of ICH-GCP, the globalisation of clinical trials has proven to be an irreversible trend. Pharmaceutical and biotechnology companies (mainly through CROs) are increasingly testing their candidate drugs in Latin America, eastern Europe and in the Asia-Pacific region. Each of these regions is composed of many different countries, each with their own clinical research regulations.

From an operational standpoint, it is not very difficult to reconcile the differences of clinical practices around the globe, although there are particularities. The operational implementation of a clinical protocol is basically the same from one place to another, and it is possible to conduct a global multi-centric study while maintaining the quality of the generated data.

From a legal standpoint, this same globalisation scenario can be slightly different. Legal systems may have a number of similarities, but unlike the ethical and operational aspects, legal differences are harder to standardise and globalise.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Vitor Harada is a Clinical Development professional with 11 years of experience. He graduated in Pharmacy and Biochemistry from the University of São Paulo (USP) and has a MBA from the Fundação Getulio Vargas (FGV). Vitor is currently a Director of Clinical Operations at ICON and responsible for the company’s office in Brazil. He is also President of ABRACRO (Brazilian Association of CROs) and one of the Professors/Coordinators of the Clinical Research Postgraduation Course of the Santa Casa de São Paulo Medical School. In the past, Vitor has worked for AstraZeneca (where he was the local Head of the Clinical Department), Pharmacia and Bristol-Myers Squibb.
spacer
Vitor Harada
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers
 
Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement